File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Anti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver

TitleAnti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver
Authors
KeywordsAdeno-associated virus
Angiostatin
B7.1
Gene therapy
Immunotherapy
Liver cancer
Issue Date2005
PublisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
Citation
International Journal Of Cancer, 2005, v. 113 n. 4, p. 670-677 How to Cite?
AbstractLiver cancer has a very poor prognosis and lacks effective therapy. We have previously demonstrated that intraportal injection of adeno-associated-viral (AAV) particles that express angiostatin lead to long-term expression of angiostatin capable of suppressing the outgrowth of EL-4 tumors in the liver. Here we combine AAV-mediated angiostatin therapy with immunotherapy by employing an AAV vector encoding the T-cell costimulator B7.1. Incubation of EL-4 cells with AAV-B7.1 viruses resulted in the rapid expression of B7.1 on the surface of 80% of EL-4 cells. Mice that were vaccinated with B7.1-engineered tumor cells rejected the tumor cells and resisted a secondary challenge with unmodified parental cells. Splenocytes from the vaccinated mice were highly cytotoxic towards parental EL-4 cells in vitro. However, the vaccinated mice failed to resist the challenge of a heavy burden of EL-4 cells. Intraportal injection of AAV particles that express angiostatin into mice that had been vaccinated 1 month earlier with B7.1-engineered tumor cells protected mice against the challenge of a heavy burden of EL-4 cells and eradicated tumors that had disseminated to the liver. The combinational therapy increased the survival rate of mice with advanced liver cancer. These encouraging results warrant investigation of the employment of anti-angiogenic therapy subsequent to cancer immunotherapy for targeting unresectable disseminated liver metastases.
Persistent Identifierhttp://hdl.handle.net/10722/83146
ISSN
2015 Impact Factor: 5.531
2015 SCImago Journal Rankings: 2.657
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorSun, Xen_HK
dc.contributor.authorKrissansen, GWen_HK
dc.contributor.authorFung, PWCen_HK
dc.contributor.authorXu, Sen_HK
dc.contributor.authorShi, Jen_HK
dc.contributor.authorMan, Ken_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorXu, Ren_HK
dc.date.accessioned2010-09-06T08:37:33Z-
dc.date.available2010-09-06T08:37:33Z-
dc.date.issued2005en_HK
dc.identifier.citationInternational Journal Of Cancer, 2005, v. 113 n. 4, p. 670-677en_HK
dc.identifier.issn0020-7136en_HK
dc.identifier.urihttp://hdl.handle.net/10722/83146-
dc.description.abstractLiver cancer has a very poor prognosis and lacks effective therapy. We have previously demonstrated that intraportal injection of adeno-associated-viral (AAV) particles that express angiostatin lead to long-term expression of angiostatin capable of suppressing the outgrowth of EL-4 tumors in the liver. Here we combine AAV-mediated angiostatin therapy with immunotherapy by employing an AAV vector encoding the T-cell costimulator B7.1. Incubation of EL-4 cells with AAV-B7.1 viruses resulted in the rapid expression of B7.1 on the surface of 80% of EL-4 cells. Mice that were vaccinated with B7.1-engineered tumor cells rejected the tumor cells and resisted a secondary challenge with unmodified parental cells. Splenocytes from the vaccinated mice were highly cytotoxic towards parental EL-4 cells in vitro. However, the vaccinated mice failed to resist the challenge of a heavy burden of EL-4 cells. Intraportal injection of AAV particles that express angiostatin into mice that had been vaccinated 1 month earlier with B7.1-engineered tumor cells protected mice against the challenge of a heavy burden of EL-4 cells and eradicated tumors that had disseminated to the liver. The combinational therapy increased the survival rate of mice with advanced liver cancer. These encouraging results warrant investigation of the employment of anti-angiogenic therapy subsequent to cancer immunotherapy for targeting unresectable disseminated liver metastases.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/homeen_HK
dc.relation.ispartofInternational Journal of Canceren_HK
dc.rightsInternational Journal of Cancer. Copyright © John Wiley & Sons, Inc.en_HK
dc.subjectAdeno-associated virusen_HK
dc.subjectAngiostatinen_HK
dc.subjectB7.1en_HK
dc.subjectGene therapyen_HK
dc.subjectImmunotherapyen_HK
dc.subjectLiver canceren_HK
dc.titleAnti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liveren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0020-7136&volume=113&issue=4&spage=670&epage=677&date=2004&atitle=Anti-angiogenic+therapy+subsequent+to+adeno-associated-virus-mediated+immunotherapy+eradicates+lymphomas+that+disseminate+to+the+liveren_HK
dc.identifier.emailMan, K: kwanman@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityMan, K=rp00417en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/ijc.20624en_HK
dc.identifier.pmid15472906-
dc.identifier.scopuseid_2-s2.0-11144316756en_HK
dc.identifier.hkuros96580en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-11144316756&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume113en_HK
dc.identifier.issue4en_HK
dc.identifier.spage670en_HK
dc.identifier.epage677en_HK
dc.identifier.isiWOS:000225893600021-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridSun, X=8599707500en_HK
dc.identifier.scopusauthoridKrissansen, GW=7004770042en_HK
dc.identifier.scopusauthoridFung, PWC=7101613315en_HK
dc.identifier.scopusauthoridXu, S=7404439649en_HK
dc.identifier.scopusauthoridShi, J=7404495444en_HK
dc.identifier.scopusauthoridMan, K=7101754072en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridXu, R=7402813857en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats